Evista and Questran drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Evista and Questran. Common interactions include pain among females.

The phase IV clinical study analyzes what interactions people who take Evista and Questran have. It is created by eHealthMe based on reports of 21 people who take Evista and Questran from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 02, 2022

21 people who take Evista and Questran together, and have interactions are studied.


What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,626 Evista users for its effectiveness, alternative drugs and more.

What is Questran?

Questran has active ingredients of cholestyramine. It is often used in diarrhea. eHealthMe is studying from 4,132 Questran users for its effectiveness, alternative drugs and more.

Number of Evista and Questran reports submitted per year:

Evista and Questran drug interactions.

Common Evista and Questran drug interactions by gender *:

female:

  1. Pain
  2. Arthralgia
  3. Acute myocardial infarction
  4. Rash
  5. Ejection fraction decreased
  6. Skin carcinoma
  7. Thrombocytopenia
  8. Thyrotoxicosis
  9. Breast cancer
  10. Hot flush

male:

n/a

Common Evista and Questran drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Basal cell carcinoma
  2. Calcium deficiency
  3. Depression
  4. Emotional distress
  5. Gallbladder disorder
  6. Pain
  7. Pain in extremity
  8. Skin cancer
  9. Vitamin d deficiency
  10. Colitis

60+:

  1. Pain
  2. Skin carcinoma
  3. Breast cancer
  4. Hot flush
  5. Alopecia
  6. Chronic kidney disease
  7. Oedema peripheral
  8. Pancreatitis
  9. Renal failure

Common conditions people have *:

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 28.57%
  2. Sleep Disorder: 5 people, 23.81%
  3. Meniere's Disease (a disorder of the inner ear that can affect hearing and balance to a varying degree): 5 people, 23.81%
  4. Irritable Bowel Syndrome: 5 people, 23.81%
  5. Herpes Virus Infection: 5 people, 23.81%
  6. High Blood Pressure: 4 people, 19.05%
  7. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 14.29%
  8. Asthma: 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Evista and Questran?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Evista and Questran interactions:

Browse all drug interactions of Evista and Questran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Evista interactions:

Browse all interactions between Evista and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Questran interactions:

Browse all interactions between Questran and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on raloxifene hydrochloride and cholestyramine (the active ingredients of Evista and Questran, respectively), and Evista and Questran (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Evista and Questran.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: